Literature DB >> 12633661

T-cell responses of vaccinated cancer patients.

Pierre G Coulie1, Pierre van der Bruggen.   

Abstract

Following vaccination with defined tumor antigens that are recognized by T cells, a small proportion of cancer patients display tumor regressions. Several reports describe anti-vaccine T-cell responses, evaluated with a variety of methods, for example, by assessing T-cell function or expression of specific TCR. However, a correlation between these T-cell responses and the tumor regressions has not yet been established. It appears that some patients display tumor regression with an unexpectedly low frequency of anti-vaccine T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633661     DOI: 10.1016/s0952-7915(03)00009-8

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  18 in total

1.  Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Authors:  Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 2.  Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.

Authors:  Marijo Bilusic; James L Gulley
Journal:  Cancer Immunol Immunother       Date:  2011-11-26       Impact factor: 6.968

3.  Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells.

Authors:  Antje Hoff; Ana-Cristina Bagû; Thomas André; Günter Roth; Karl-Heinz Wiesmüller; Brigitte Gückel; Roland Brock
Journal:  Cancer Immunol Immunother       Date:  2010-05-29       Impact factor: 6.968

4.  Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway.

Authors:  Emmanuelle Godefroy; Olivier Manches; Brigitte Dréno; Tsivia Hochman; Linda Rolnitzky; Nathalie Labarrière; Yannick Guilloux; Judith Goldberg; Francine Jotereau; Nina Bhardwaj
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

5.  Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.

Authors:  Viggo F Van Tendeloo; Ann Van de Velde; Ann Van Driessche; Nathalie Cools; Sébastien Anguille; Kristin Ladell; Emma Gostick; Katrien Vermeulen; Katrien Pieters; Griet Nijs; Barbara Stein; Evelien L Smits; Wilfried A Schroyens; Alain P Gadisseur; Inge Vrelust; Philippe G Jorens; Herman Goossens; I Jolanda de Vries; David A Price; Yusuke Oji; Yoshihiro Oka; Haruo Sugiyama; Zwi N Berneman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-14       Impact factor: 11.205

6.  Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.

Authors:  Yun Lin; Humilidad F Gallardo; Geoffrey Y Ku; Hao Li; Gregor Manukian; Teresa S Rasalan; Yinyan Xu; Stephanie L Terzulli; Lloyd J Old; James P Allison; Alan N Houghton; Jedd D Wolchok; Jianda Yuan
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

7.  Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

Authors:  Yanyan Lou; Gang Wang; Gregory Lizée; Grace J Kim; Steven E Finkelstein; Chiguang Feng; Nicholas P Restifo; Patrick Hwu
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

Review 8.  Filamentous bacteriophage fd as an antigen delivery system in vaccination.

Authors:  Antonella Prisco; Piergiuseppe De Berardinis
Journal:  Int J Mol Sci       Date:  2012-04-24       Impact factor: 6.208

9.  A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.

Authors:  Sebastian Attig; Leah Price; Sylvia Janetzki; Michael Kalos; Michael Pride; Lisa McNeil; Tim Clay; Jianda Yuan; Kunle Odunsi; Axel Hoos; Pedro Romero; Cedrik M Britten
Journal:  J Transl Med       Date:  2011-07-11       Impact factor: 5.531

10.  Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.

Authors:  Jitka Fučíková; Daniela Rožková; Hana Ulčová; Vít Budinský; Klára Sochorová; Kateřina Pokorná; Jiřina Bartůňková; Radek Špíšek
Journal:  J Transl Med       Date:  2011-12-30       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.